NCT03693339 is a Phase 2 clinical trial of Capmatinib in Cancer, sponsored by Asan Medical Center.

Who is sponsoring NCT03693339?

NCT03693339 is sponsored by Asan Medical Center.

What drugs are being tested in NCT03693339?

Interventions in NCT03693339: Capmatinib.

What condition does NCT03693339 study?

NCT03693339 studies Cancer, Lung Cancer Metastatic, MET Gene Mutation.

Is NCT03693339 still recruiting?

NCT03693339 is currently status unknown. Last updated 3 October 2018.

Last reviewed 2018-10-03 · How we verify

NCT03693339

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation

Status unknown Phase 2 Last updated 3 October 2018

What this trial tests

Phase 2 trial testing Capmatinib in Cancer in 27 participants. Status unknown.

Timeline

30 October 2018

Primary endpoint
30 June 2020

30 June 2022

Quick facts

Lead sponsor	Asan Medical Center
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	27
Start date	30 October 2018
Primary completion	30 June 2020
Estimated completion	30 June 2022
Sites	1 location across South Korea

Drugs / interventions tested

Capmatinib (CAPMATINIB) — full drug profile →

Conditions studied

Cancer — all drugs for Cancer →
Lung Cancer Metastatic — all drugs for Lung Cancer Metastatic →
MET Gene Mutation — all drugs for MET Gene Mutation →

Sponsor

Asan Medical Center

Who can join

18 and older, any sex, with Cancer or Lung Cancer Metastatic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a phase II, single-arm, open label study under an umbrella trial for NSCLC. This clinical study is targeted for the patients who harbor exon 14 skipping mutation of MET and all patients will be treated with Capmatinib. The treatment period begins on Day 1 of Cycle 1 and 1 cycle consists of 28 days.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis.
Liang H, Wang M. · · 2020 · cited 89× · PMID 32273721 · DOI 10.2147/ott.s231257
Safety and Tolerability of c-MET Inhibitors in Cancer.
Puccini A, Marín-Ramos NI, Bergamo F, Schirripa M, et al · · 2019 · cited 89× · PMID 30649748 · DOI 10.1007/s40264-018-0780-x
Current and future treatment options for <i>MET</i> exon 14 skipping alterations in non-small cell lung cancer.
Hong L, Zhang J, Heymach JV, Le X. · · 2021 · cited 50× · PMID 33643443 · DOI 10.1177/1758835921992976
A narrative review of MET inhibitors in non-small cell lung cancer with <i>MET</i> exon 14 skipping mutations.
Santarpia M, Massafra M, Gebbia V, D'Aquino A, et al · · 2021 · cited 44× · PMID 33889528 · DOI 10.21037/tlcr-20-1113
Predictive and Prognostic Biomarkers for Lung Cancer Bone Metastasis and Their Therapeutic Value.
Chai X, Yinwang E, Wang Z, Wang Z, et al · · 2021 · cited 36× · PMID 34722241 · DOI 10.3389/fonc.2021.692788
The METeoric rise of MET in lung cancer.
Friedlaender A, Drilon A, Banna GL, Peters S, et al · · 2020 · cited 36× · PMID 32888330 · DOI 10.1002/cncr.33159
Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?
Spagnolo CC, Ciappina G, Giovannetti E, Squeri A, et al · · 2023 · cited 21× · PMID 37373267 · DOI 10.3390/ijms241210119
Meeting an un-MET need: Targeting MET in non-small cell lung cancer.
Michaels E, Bestvina CM. · · 2022 · cited 17× · PMID 36338701 · DOI 10.3389/fonc.2022.1004198

Verify or expand the search:

Other trials of Capmatinib

Trials testing the same drug.

NCT06054191 — Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations · Phase 2 · not yet recruiting
NCT05703516 — A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea · recruiting
NCT05642572 — Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A L · Phase 2 · recruiting
NCT05488314 — A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer · Phase 1, PHASE2 · active not recruiting
NCT05243641 — Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients W · Phase 1, PHASE2 · terminated

Other recruiting trials for Cancer

Currently open trials in the same condition.

NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting

Other Asan Medical Center trials

Trials by the same sponsor.

NCT07530393 — Blood Viscosity and Outcomes After Elective Craniotomy · not yet recruiting
NCT07010497 — A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Be · Phase 2 · recruiting
NCT07382505 — Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cerv · not yet recruiting
NCT07489092 — Feasibility of a Digital Rehabilitation Platform in Patients After ICU Discharge · NA · recruiting
NCT07431762 — Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Hear · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03693339 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Asan Medical Center
Last refreshed: 3 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03693339.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing